查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471213

疫苗契约製造市场：按类型、特征和应用分类 - 2024-2030 年全球预测

Vaccine Contract Manufacturing Market by Type (Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine), Function (Downstream, Upstream), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

疫苗契约製造市场规模预计2023年为50.6亿美元，2024年达到55.1亿美元，预计2030年将达到93.9亿美元，复合年增长率为9.21%。

疫苗契约製造是指将疫苗製造过程外包给称为受託製造厂商（CMO）的第三方。这些专业公司拥有在从最初开发到全面生产和包装的各个阶段生产疫苗的专业知识、设备和设施。疫苗製造商与 CMO 合作，加速开发和製造流程、利用专业知识、控製成本并确保供应链弹性。疫苗契约製造市场包括以合约形式向製药业提供各种服务的公司。这包括各阶段的疫苗生产，从临床前测试等早期开发到大规模商业生产。这通常包括抗原製造等上游工程和填充、精加工和包装等下游製程。疫苗契约製造是需要额外疫苗生产能力和专业知识的製药公司、生物技术公司和研究机构的重要合作伙伴。在全球感染疾病数量增加、政府对疫苗开发的监管和支持加强以及新生儿和儿童疫苗接种增加的背景下，疫苗的契约製造正在增长。然而，市场面临某些挑战，包括疫苗相关的高成本和缺乏适当的储存基础设施。同时，mRNA疫苗技术的进步以及与政府和非政府组织的战略联盟与合作正在为疫苗契约製造市场创造潜在的商机。

主要市场统计
基准年[2023] 50.6亿美元
预测年份 [2024] 55.1亿美元
预测年份 [2030] 93.9亿美元
复合年增长率（%） 9.21%

类型：更多地采用减毒疫苗来增强免疫系统

减毒疫苗使用活病毒疫苗的、弱化的病毒或细菌，不会对免疫系统健康的人造成疾病。这种类型的疫苗会产生强烈的免疫反应，通常需要较少的剂量即可获得长期免疫力。 DNA 疫苗利用病原体的部分遗传物质来引发免疫反应。这种药物使体内细胞产生病原体特异性抗原并刺激特异性免疫反应。 DNA 疫苗仍然是一项相对较新的技术，在开发速度和稳定性方面具有潜在优势，使其成为契约製造的有趣途径。灭活疫苗含有已透过物理或化学处理杀死的病毒或细菌。这些疫苗本身不存在引起疾病的风险，并且稳定，适合多种环境。灭活疫苗通常需要佐剂来增强免疫反应，并且可能需要多次剂量。次单位疫苗仅包含病毒或细菌的必需抗原，而不是整个病原体。这种方法最大限度地减少了副作用的风险，当病原体无法在试管内培养或不需要接种整个生物体时特别有用。类毒素疫苗是由致病细菌产生的灭活有毒化合物，而不是细菌本身。这些疫苗训练免疫系统抵抗天然毒素，并在免疫者遇到实际病原体时提供保护。这种疫苗对产生毒素是导致疾病的主要原因的细菌特别有效，例如导致破伤风的破伤风梭菌。

功能：增加下游製剂的使用，涉及生物製品的精製和製剂

下游加工是指疫苗生产中对大宗产品进行精製和精製以满足监管标准和品质要求的阶段。关键的下游步骤包括细胞和病毒颗粒分离、污染物去除以及疫苗浓缩和配製。下游加工的需求源于在向公众施用疫苗之前确保疫苗的安全性、纯度和有效性的需要。疫苗生产的上游工程包括疫苗生产生系统的繁殖和初始收穫所需的所有步骤。这通常涉及培养产生疫苗抗原的细胞或微生物。对尖端上游工程技术的偏好源于对一致、可扩展和高产量疫苗生产的基本需求。

应用：疫苗的契约製造越来越有可能用于人类，以保护人们免受感染疾病。

人类疫苗契约製造的需求主要是由世界保护人们免受感染疾病的需要所驱动的。该部门包括生产适用于各种情况的疫苗，从每年的流感疫苗注射到针对新出现的公共卫生威胁（包括 COVID-19）的免疫接种。兽用疫苗的疫苗契约製造可满足动物群体（包括牲畜和伴同性动物）的疫苗接种需求。该部分保证动物健康，这对于粮食安全和预防感染人类的通用感染疾病至关重要。

区域洞察

美洲地区拥有美国、加拿大等国家，医疗体系先进，居民健康意识较高。美国是疫苗研究的着名国家。生物专利生态系统充满活力，政府、工业界和学术界积极投资新疫苗技术。在南美洲，生物技术投资的增加、政府对药品生产的激励措施、公共卫生支出的增加以及生物製造设施的存在正在推动疫苗契约製造的采用。欧洲拥有成熟的疫苗契约製造製造业，受益于高品质的製造标准和严格的监管环境。欧盟（EU）国家积极从事研究和创新，拥有强大的生物技术公司和研究机构网络。中东地区历来依赖进口疫苗，但目前正逐步发展疫苗生产能力，阿联酋和沙乌地阿拉伯等国投资建设当地生产设施。非洲市场深受全球卫生倡议和合作伙伴关係的影响，这些倡议和合作伙伴关係致力于为各种经济背景的人们提供疫苗。由于人口众多、医疗保健支出不断增加以及人们对疫苗接种需求的认识不断增强，亚太地区是一个充满活力且快速增长的市场。印度和中国等国家处于领先地位，拥有重要的生产设施，为世界疫苗供应做出了贡献。中国正大力投资生技和疫苗创新，强调技术升级的重要性。日本公司正在投资下一代疫苗，包括基于 mRNA 和 DNA 的疫苗，政府也正在透过措施支持研究。

FPNV定位矩阵

FPNV定位矩阵对于评估疫苗契约製造市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对疫苗契约製造市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动以及突破性产品开发的见解。

本报告解决了以下关键问题：

1.疫苗契约製造市场的市场规模与预测为何？

2.在疫苗契约製造市场的预测期内，我们应该考虑投资哪些产品和应用？

3.疫苗契约製造市场的技术趋势和法规结构是什么？

4.疫苗契约製造市场主要厂商的市场占有率是多少？

5.进入疫苗契约製造市场的合适形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 疫苗需求增加扩大了合约製造商的产能
      • 合约服务的主要好处包括节省成本和时间
      • 世界各地的疫苗接种率
    • 抑制因素
      • 成熟疫苗製造商的有限外包
    • 机会
      • 全球需求不断增长，以满足不断增长的不同年龄层人口的需求
      • 创新和强大的疫苗产品线
      • 政府对加速疫苗生产的有利观点和指导方针
    • 任务
      • 製药公司在内部进行生产业务以获得策略控制
  • 市场区隔分析
    • 类型：更多地采用减毒疫苗来增强免疫系统
    • 特点：增加下游加工配方的使用，包括生物产品精製和配方
    • 应用：增加人类用于保护人们免受感染疾病的疫苗契约製造的潜力
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 疫苗契约製造市场：依类型

  • 介绍
  • 减毒疫苗
  • DNA疫苗
  • 灭活疫苗
  • 次单位疫苗
  • 类毒素疫苗

第七章 疫苗契约製造市场：依功能分类

  • 介绍
  • 下游
  • 上游

第八章疫苗契约製造市场：依应用分类

  • 介绍
  • 对于人类
  • 兽医

第九章 北美和南美疫苗契约製造市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太疫苗契约製造市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲疫苗契约製造市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-430D42AA0DC4

[199 Pages Report] The Vaccine Contract Manufacturing Market size was estimated at USD 5.06 billion in 2023 and expected to reach USD 5.51 billion in 2024, at a CAGR 9.21% to reach USD 9.39 billion by 2030.

Vaccine contract manufacturing refers to outsourcing vaccine production processes to third-party organizations, known as contract manufacturing organizations (CMOs). These specialized companies possess the expertise, equipment, and facilities to produce vaccines at various stages, from initial development to full-scale production and packaging. Vaccine manufacturers partner with CMOs to expedite the development and manufacturing process, leverage specialized capabilities, manage costs, and ensure supply chain flexibility. The vaccine contract manufacturing market encompasses companies that provide a range of services on a contract basis for the pharmaceutical industry. This includes the production of vaccines at various stages, from early-stage development, such as preclinical trials, through to large-scale commercial production. It often involves upstream processes, such as antigen production, and downstream processes, including filling, finishing, and packaging. Vaccine contract manufacturers serve as critical partners for pharmaceutical firms, biotechnology companies, and research institutions that require additional capability or expertise in vaccine production. The vaccine contract manufacturing is growing due to increasing outbreaks of infectious diseases worldwide, growing governmental regulations and support for vaccine development, and rising vaccinations of newborns and children. However, the market faces certain challenges, such as the high cost associated with vaccines and the lack of proper storage infrastructure. On the other hand, technological advancements in mRNA vaccine technology and strategic partnerships and collaborations with governments and non-governmental organizations present potential opportunities for the vaccine contract manufacturing market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.06 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 9.39 billion
CAGR (%) 9.21%

Type: Growing adoption of attenuated vaccines to enhance immune systems

An attenuated vaccine uses a live version of the virus or bacteria that has been weakened, which cannot cause disease in people with healthy immune systems. This type of vaccine elicits a strong immune response and often requires fewer doses for long-term immunity. DNA vaccines employ a piece of genetic material from a pathogen to elicit an immune response. They direct the body's cells to produce an antigen that is native to the pathogen, prompting a specific immune response. DNA vaccines are still a relatively new technology and offer potential advantages in speed of development and stability, making them an interesting avenue for contract manufacturing. Inactivated vaccines contain viruses or bacteria that have been killed through physical or chemical processes. These vaccines do not pose a risk of causing the disease itself and are stable, making them suitable for a broad range of environments. Inactivated vaccines generally require adjuvants to enhance the immune response and may require multiple doses. Subunit vaccines include only the essential antigens of a virus or bacteria-rather than the whole pathogen. This approach minimizes the risk of side effects and is particularly useful when the pathogen cannot be cultivated in vitro or when the whole organism is unnecessary for immunization. Toxoid vaccines contain inactivated toxic compounds produced by bacteria that cause illness rather than the bacteria itself. These vaccines train the immune system to fight off the natural toxin, offering protection if the immunized individual ever encounters the actual pathogen. They are particularly useful for bacteria, such as Clostridium tetani, the cause of tetanus, where toxin production is the main cause of disease.

Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts

Downstream processing refers to the phase of vaccine manufacturing where the bulk product is refined and purified to meet regulatory standards and quality requirements. Key steps in downstream processing include the separation of cells and virus particles, removal of contaminants, and concentration and formulation of the vaccine. The need for downstream processing arises from the necessity to ensure that vaccines are safe, pure, and effective before they can be administered to the public. Upstream processing in vaccine manufacturing includes all steps necessary for the growth and initial harvest of the vaccine-producing biological system. This generally involves the culturing of cells or microorganisms that generate the vaccine antigen. The preference for cutting-edge upstream processing technologies stems from the fundamental need for consistent, scalable, and high-yield vaccine production.

Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases

The need for vaccine contract manufacturing in the human use segment is primarily driven by the global need to protect populations against infectious diseases. This segment encompasses the production of vaccines for a vast range of conditions, from annual influenza shots to immunizations against emerging public health threats, including COVID-19. Vaccine contract manufacturing for veterinary applications addresses the need for immunizations within animal populations, including both livestock and companion animals. The segment ensures the health of animals, which is crucial for food security and the prevention of zoonotic diseases that can transfer to humans.

Regional Insights

The Americas region, with countries such as the United States and Canada, is characterized by advanced healthcare systems and a high degree of health awareness among the population. The United States stands as a prominent country in vaccine research. It has a vibrant ecosystem for biotech patents, with the government, industry, and academia actively investing in new vaccine technologies. In South America, increasing investment in biotechnology, government incentives for pharmaceutical manufacturing, growing public health expenditure, and the presence of bio-manufacturing facilities support the adoption of vaccine contract manufacturing. Europe has a mature vaccine contract manufacturing industry, benefiting from high-quality manufacturing standards and a stringent regulatory landscape. European Union (EU) countries actively engage in research and innovation, with a strong network of biotech firms and research institutes. The Middle East, while historically reliant on imported vaccines, is gradually developing its vaccine manufacturing capabilities, with nations including the United Arab Emirates and Saudi Arabia investing in local production facilities. Africa's market is heavily influenced by global health initiatives and partnerships focused on providing access to vaccines for all economic backgrounds. Asia Pacific represents a dynamic and rapidly growing vaccine contract manufacturing market due to its large population base, increasing healthcare expenditures, and growing awareness of the need for immunizations. Nations such as India and China are at the forefront, with a substantial number of manufacturing facilities contributing to the global vaccine supply. China has made significant investments in biotech and vaccine innovation, emphasizing the importance of technological upgrades. Japanese companies are investing in next-generation vaccines, including mRNA and DNA-based vaccines, while the government supports research through initiatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccine Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccine Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Attenuated Vaccine
    • DNA Vaccines
    • Inactivated Vaccine
    • Subunit Vaccines
    • Toxoid Vaccines
  • Function
    • Downstream
      • Analytical & QC studies
      • Fill & Finish Operations
      • Packaging
    • Upstream
      • Bacterial Expression Systems
      • Baculovirus or Insect Expression Systems
      • Mammalian Expression Systems
      • Yeast Expression Systems
  • Application
    • Human Use
    • Veterinary
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccine Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccine Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Vaccine Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Vaccine Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Vaccine Contract Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
      • 5.1.1.2. Key advantages such as cost and time saving offered by contract services
      • 5.1.1.3. Vaccination coverage across the globe
    • 5.1.2. Restraints
      • 5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising global demand to cater to the growing population of varied age groups
      • 5.1.3.2. Innovation and robust vaccine pipeline
      • 5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of attenuated vaccines to enhance immune systems
    • 5.2.2. Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
    • 5.2.3. Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Vaccine Contract Manufacturing Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccine
  • 6.3. DNA Vaccines
  • 6.4. Inactivated Vaccine
  • 6.5. Subunit Vaccines
  • 6.6. Toxoid Vaccines

7. Vaccine Contract Manufacturing Market, by Function

  • 7.1. Introduction
  • 7.2. Downstream
  • 7.3. Upstream

8. Vaccine Contract Manufacturing Market, by Application

  • 8.1. Introduction
  • 8.2. Human Use
  • 8.3. Veterinary

9. Americas Vaccine Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vaccine Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
    • 12.3.2. Oxford Acquires ABL Europe From Institut Merieux For EUR 15 Mn
    • 12.3.3. Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. VACCINE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VACCINE CONTRACT MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ATTENUATED VACCINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ATTENUATED VACCINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACULOVIRUS OR INSECT EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACULOVIRUS OR INSECT EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VETERINARY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VETERINARY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTIO